Abstract
Greystone Research Associates is pleased to announce the publication of a new
market study. Needle Array Drug Delivery Systems: Devices, Therapeutic
Markets, Strategies and Prospects is a comprehensive evaluation and
analysis of the technology, devices, product development strategies and
participants that comprise the needle array segment of the medical device
sector.
The study is designed to provide drug company decision makers, drug delivery
developers, device designers, healthcare marketers, and supply chain
participants with a detailed understanding of the economics, technologies,
healthcare segments and commercial opportunities for needle arrays and devices
in the delivery of therapeutic drugs. Provider organization business managers,
healthcare administrators and investors will also benefit from this study.
Evolving Materials Technology and Minimally Invasive Therapeutics
Evolution in drug delivery device design is changing the way a growing number
of therapeutic substances are administered. This trend is being fostered by
the desire by patients for more user friendly methods for self-medicating, and
by the need for safer, more reliable drug products that improve compliance.
For drugs designed to be delivered across the skin, needle arrays are viewed
as an approach that addresses these key healthcare objectives.
Needle arrays offer several advantages when compared to conventional needle
technologies including being minimally invasive due to their small
cross-sectional area, providing precise penetration depth under the skin,
inducing minimal trauma during insertion due to the advanced tip designs, and
increased functionality. Important needle array fabrication technologies
include micromachining, microforming, LIGA, and structured films. Prominent
needle array form factors include solid (coated and uncoated) needle arrays,
hollow needle arrays, dissolving needle arrays, programmable needle arrays,
and phase transition needle arrays.
Needle array technology is attaining commercial viability at a time when drug
developers are faced with new challenges as they assess ways to administer a
new class of compounds with significant therapeutic potential. The widespread
availability of rapid throughput screening is accelerating the discovery of
large-molecule therapeutic compounds that cannot tolerate passage through the
digestive system, requiring pharmaceutical companies to forego oral
formulations and select alternate routes of administration.
Feature Summary
- Provides assessments of marketed and development stage needle array drug
delivery systems
- Analyzes and evaluates needle array technology and product research &
development activities, and assesses the medical market potential for existing
and probable future products
- Analyzes proprietary technologies and market development issues
- Provides detailed descriptions of medical needle array drug delivery
business opportunities, market demographics, and business strategies
- Provides market data and forecasts to 2016
- Profiles needle array product and technology participants, their
activities, business strategies, and corporate alliances and affiliations
- Evaluates the impact of economic, technology, and regulatory factors on
the commercial potential of microneedle systems
Report Format and Availability
This report is available in electronic format. A site license for a single
physical location and an Enterprise license are also available.
Methodology
Research methodology is based on primary research in the form of in-depth
interviews with key market participants, technology developers, distributors,
industry experts, and market influencers, a list that includes regulatory
officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including
trade journal articles, technical literature, industry publications, company
data sheets and published information, and statistical data from government
agencies and trade associations. Forecasts and projections of market demand
and future market activity are derived using standard modeling and statistical
techniques.
Table of Contents
Executive Summary
Active Transdermal Delivery Market Dynamics
- Drug Classes, Indications and Demand
- The Needle Array Ecosystem
- What's Driving the Growth in Alternative Drug Delivery?
- Competitive Landscape
- Risk Factors
Needle Array Architecture, Technology & Fabrication
- Needle Array Design Strategies
- Solid Needle Arrays
- Hollow Needle Arrays
- Coated Needle Arrays
- Dissolvable Needle Arrays
- Needle Array Geometries &Form Factors
- Needle Array Manufacturing
- Material Selection Issues
- Fabrication Techniques
- Emerging Fabrication Methods
Needle Array Delivery Systems - Assessments & Commercial Prospects
- Syringe-mounted Arrays
- Solid Needle Arrays
- sMTS
- Macroflux
- MicroCor
- Micropatch
- OnVax
- Unbranded (Nanomed)
- Hollow Needle Arrays
- hMTS
- Micro-Trans
- Unbranded (MyLife Technologies)
- Dissolvable Arrays
- VaxMAT
- Unbranded (BioSerenTach)
- Metal Film Needle Arrays
- Phase Transition Needle Array Patches
- Unbranded (BioPharm Solutions)
- Programmable Needle Array Patch
- Pyraderm
- Unbranded (Janisys)
- Spring Powered Needle Arrays
- Unbranded (PKA SoftTouch)
- Customizable Needle Arrays
- Unbranded (Micropoint Technologies)
Near-Terms Markets for Needle Arrays - Assessments & Forecasts
- Dermatology/Cosmetic Surgery
- Diabetes
- Genetic/DNA/Nucleotide Therapeutics
- Oncology
- Osteoporosis
- Reproductive Medicine
- Vaccines
Market Factors
- Regulatory Considerations
- Patient Preferences and Compliance
- Managed Care Initiatives
Company Profiles
Needle Array Drug Delivery Systems: Devices, Therapeutic Markets, Strategies and Prospects published by Greystone Research Associates in February 21, 2012. This report price starts from US $ 2850.
The contents of this page may be different from the latest version. Please contact us for details.
